Fears over vaccines block

Share this article:
The weekly Cancer Letter says recent Capitol Hill testimony by the acting director of the National Cancer Institute (NCI) suggests that human papilloma virus (HPV) vaccines, objected to by the religious right, might have approval blocked by the FDA. Both Merck and GlaxoSmithKline are developing 
vaccines.

According to the Cancer Letter, NCI acting director John Niederhuber seemed to downplay the vaccines' importance for US women, notwithstanding one's success in an NCI-sponsored trial, when he appeared before the House Appropriations Subcommittee on Labor, HHS and Education.

However, in the third world, Niederhuber said, “the impact of this could be just absolutely huge.” The Cancer Letter says social conservatives are expected to oppose HPV vaccines at FDA the same way they opposed the emergency contraceptive Plan B.

The letter goes on to  quote Reproductive Health Technologies Project president Kirsten Moore as saying Niederhuber's testimony sounded “like the birth of a convenient excuse not to look at what HPV vaccines could do for this country.”

Some religious right advocates claim that HPV vaccines, like Plan B, would encourage sexual promiscuity, especially among the young.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...